Stocks traded higher for a second straight day on hopes the Federal Reserve chief will confirm expectations of easier monetary policy at a central banking summit this week.US Marketsread more
A Volkswagen spokesperson called the report that CEO Herbert Diess is interested in buying a stake in Tesla "completely unfounded."Technologyread more
"My sense was we've added accommodation, and it wasn't required in my view," George tells CNBC's Steve Liesman.Investingread more
Apple plans to unveil three new iPhones in September, including two new "Pro" models and a successor to the iPhone XR, Bloomberg reported Thursday.Technologyread more
Corporate profits posted modest growth in the second quarter as companies brace for slowing global growth.Retailread more
Former Prudent Bear Fund manager David Tice is urging investors to brace for a massive downturn.Trading Nationread more
Kraft has filed a contempt motion against the CFTC over a press release announcing the $16 million fine to settle claims of manipulating wheat prices.Food & Beverageread more
A ruling against J&J could mean more big payouts in similar cases across the country.Health and Scienceread more
Michael Burry thinks GameStop still has upside as Sony's and Microsoft's upcoming consoles will likely have physical optic drives.Investingread more
Target shares closed Wednesday up more than 20%, after the retailer reported impressive profit growth and a spike in traffic that surpassed analysts' expectations.Retailread more
German Chancellor Angela Merkel said a solution to the Irish "backstop" is possible before the October 31 Brexit deadline.Europe Economyread more
Johnson & Johnson said Wednesday it would buy robotic surgery firm Auris Health for $3.4 billion in cash.
The purchase gives J&J, one of the world's largest maker of health products, an entry into robotics and builds on the company's partnership with Alphabet's Verily.
"In this new era of health care, we're aiming to simplify surgery, drive efficiency, reduce complications and improve outcomes for patients, ultimately making surgery safer," said Ashley McEvoy, company group chair of consumer medical devices, in a press release. "Collectively, these technologies, together with our market-leading medical implants and solutions, create the foundation of a comprehensive digital ecosystem to help support the surgeon and patient before, during and after surgery."
The company is divided in three main business units: pharmaceuticals, medical devices and consumer products. J&J's medical device business has been lagging, with sales falling 4 percent to $6.67 billion in the fourth quarter of 2018. The health-care company has vowed to improve performance through acquisitions and divestitures.
Last year, J&J divested its LifeScan blood glucose monitor business after exiting the insulin pump market.
Bloomberg reported last month that J&J was pursing an acquisition of Auris Health, a privately held developer of robotic technologies. J&J said Wednesday it's creating a "connected digital ecosystem" that uses data and robotic technology to guide surgeon through procedures and improve patient treatment.
The surgical instruments business is expected to reach more than $12 billion by 2025, with the biggest players in the space including J&J, Medtronic, and Intuitive Surgical.
J&J CEO Alex Gorsky noted in a fourth-quarter earnings call last month that investors would see "continued news about our robotics platform over the course of 2020 and beyond."
"What we want to make sure is that we get out in a timely manner," he said, "but that we're also out in a manner that ensures we're competitive and ensures, ultimately, that we're making an even bigger difference in this area as we go forward."
The transaction is expected to close by the end of the second quarter of 2019.
J&J's stock was slightly higher in premarket trading Wednesday. The stock is up nearly 4 percent since the beginning of this year. Shares are more than 2 percent higher over the last 12 months.
--CNBC's Angelica LaVito contributed to this report.